Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 8, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 150,000 ordinary shares of 25 pence each.
- Purchase Price: 1,388.02 pence per share.
- Treasury Holdings: Following the purchase, the company holds 250,575,678 shares in Treasury.
- Shares in Issue: 5,747,891,328 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 150,000 shares on February 8, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,747,891,328) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count of 250,575,678.
- Note that this filing is a notification of a specific share buyback event and does not contain quarterly or annual financial results.